Touchlight, a biotechnology company pioneering enzymatic DNA production, has signed a development and manufacturing pipeline agreement with Versameb AG, a pre-clinical stage company focused on discovering and developing RNA-based therapeutics.   The agreement enables Versameb to use Touchlight’s proprietary doggybone DNA (dbDNA) vector technology to support the development of novel mRNA-based therapeutics addressing unmet needs in urology and oncology. This includes Versameb’s lead candidate V...